Exactech, Inc. (EXAC) Updates Q3 Earnings Guidance

Exactech, Inc. (NASDAQ:EXAC) updated its third quarter earnings guidance on Thursday. The company provided earnings per share guidance of $0.19-0.21 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.24. The company issued revenue guidance of $61.4 million (prior: $60.5-62.5 million), compared to the consensus revenue estimate of $61.64 million.

A number of research analysts recently issued reports on the stock. Gabelli reiterated a buy rating on shares of Exactech in a research report on Monday, July 31st. BidaskClub upgraded shares of Exactech from a sell rating to a hold rating in a research report on Friday, August 18th.

Exactech, Inc. (NASDAQ EXAC) traded down 1.49% on Thursday, hitting $33.05. 18,988 shares of the company were exchanged. Exactech, Inc. has a 52 week low of $22.20 and a 52 week high of $34.25. The stock has a 50 day moving average of $31.52 and a 200 day moving average of $29.81. The company has a market capitalization of $472.48 million, a price-to-earnings ratio of 3305.00 and a beta of 1.01.

Exactech (NASDAQ:EXAC) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $67.30 million during the quarter, compared to analyst estimates of $67.75 million. Exactech had a return on equity of 7.39% and a net margin of 0.30%. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.31 earnings per share. Analysts predict that Exactech, Inc. will post $1.29 EPS for the current fiscal year.

In other Exactech news, Director Fern Watts sold 1,013 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $29.04, for a total transaction of $29,417.52. Following the completion of the transaction, the director now owns 4,727 shares of the company’s stock, valued at $137,272.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 28.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/10/12/exactech-inc-exac-updates-q3-earnings-guidance.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Earnings History and Estimates for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply